Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: subgroup analyses by autoantibody status and skin score.
Masataka KuwanaYannick AllanoreChristopher P DentonJörg Hw DistlerVirginia SteenZsuzsanna H McMahanMarco Matucci-CerinicMaureen D MayesElizabeth R VolkmannCorinna MiedeMartina GahlemannManuel Quaresma LicMargarida AlvesAnastasiia KozlovaPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2021)
In patients with SSc-ILD, no heterogeneity was detected in the treatment effect of nintedanib in reducing the annual rate of decline in FVC across subgroups based on ATA status, mRSS, and SSc subtype.